Kidney News

Diabetes and Kidney Disease 2019: August Special Section

Capture_title_0.PNGDiabetes is the second most common cause of kidney failure in the United States. Diabetic Kidney Disease (DKD) encompasses structural and functional abnormalities involving the kidneys. Clinically, these changes result in hypertension, proteinuria, and progressive decline in kidney function, ultimately leading to ESKD. Diabetic kidney disease accounts for more than 40% of all ESKD In the United States.

Precision Medicine 2019: March Special Section

Kidney News is pleased to present this edition’s special section on precision medicine. The ability to derive diagnosis and care, specific to the individual patient and the exact timing and nature of their disease process, is anticipated to result in a huge leap forward in the efficacy and safety of treatment. A PubMed search revealed more than 50,000 articles about this topic, including more than 1600 articles when restricted to “kidney,” and the rate of new articles is rapidly climbing. It thus seemed appropriate to review this approach with our audience.

Kidney Watch 2019: February Special Section

final 2017_1.jpgFrom key medical advances to progress in the policy arena, 2019 will be a pivotal year in kidney care. Read about the top areas to watch in our special section, Kidney Watch 2019.

2018 in Review: Top 10 Kidney News Articles

2018 brought another successful year of nephrology coverage by ASN Kidney News and Kidney News Online. The two publications covered a broad spectrum of topics within nephrology and continued their strong record of informing the nephrology community.

The following are the 10 most read articles of the last year. The first 5 articles are from ASN Kidney News and the following 5 from Kidney News Online.

ASN Kidney News

Otsuka’s JYNARQUE™ (tolvaptan) is the first treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) approved by FDA

"The progressive nature of ADPKD means that kidney function gets worse over time, eventually leading to end-stage renal disease. This progression happens more rapidly for some patients than others.” said Michal Mrug, M.D., Associate Professor at the University of Alabama at Birmingham and investigator on the REPRISE trial. “Today’s approval is great news for adults at risk of rapidly progressing ADPKD because by slowing the decline in kidney function, this therapy may give them more time before kidney transplant or dialysis.”

U.S. Opioid Crisis: July Special Section


The July issue of Kidney News features a special section on the US opioid epidemic and the correlation with kidney disease.

 

Interactive Map

Pages